A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II trial of Doxil on day 1 and vinorelbine on days 1 and 2 in women with
metastatic breast cancer. Administered every 28 days. A study to assess the safety and
efficacy of Doxil and vinorelbine in metastatic breast cancer.